CompletedPhase 2NCT00238121

Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer

Studying Carcinosarcoma of the corpus uteri

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Cancer Institute (NCI)
Principal Investigator: Gini Fleming
University of Chicago Comprehensive Cancer Center
Intervention: sorafenib tosylate(drug)
Enrollment: 56 enrolled
Eligibility: 18 years · FEMALE
Timeline: 2005 – 2010

Study locations (7)

City of Hope Medical Center, Duarte, California, United States
University of Southern California, Los Angeles, California, United States
Decatur Memorial Hospital, Decatur, Illinois, United States
Central Illinois Hematology Oncology Center, Springfield, Illinois, United States
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Ontario, Canada
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00238121 on ClinicalTrials.gov

Other trials for Carcinosarcoma of the corpus uteri

Additional recruiting or active studies for the same condition.

See all trials for Carcinosarcoma of the corpus uteri →

← Back to all trials